Tricyclic Antidepressants in Functional Dyspepsia

Mechanism of Action and Efficacy

Tricyclic antidepressants function as "gut-brain neuromodulators" rather than simply antidepressants, affecting visceral hypersensitivity through peripheral and central nervous system actions, and they inhibit serotonin and noradrenergic reuptake while blocking muscarinic, α1-adrenergic, and histamine receptors, which modulates gut motility, secretion, and sensation, according to the American Gastroenterological Association 1, 2
The therapeutic effect of tricyclic antidepressants takes several weeks to manifest and is independent of antidepressant effects on mood, with the British Society of Gastroenterology supporting their use as second-line therapy for refractory functional dyspepsia 1, 2

Common adverse effects of tricyclic antidepressants include dry mouth, constipation, drowsiness, and sedation due to anticholinergic properties, with a higher withdrawal rate due to adverse effects compared to placebo, as reported by the American Gastroenterological Association 1, 2
Secondary amine tricyclic antidepressants, such as desipramine and nortriptyline, may be better tolerated due to lower anticholinergic effects, particularly in patients with constipation-predominant symptoms, according to the American Gastroenterological Association 1, 2

The overall certainty of evidence for tricyclic antidepressants in functional dyspepsia is LOW, based on heterogeneous trials with varying doses and different tricyclic antidepressant types, with most positive studies using higher doses, as reported by the American Gastroenterological Association 1, 2
Tricyclic antidepressants show a significantly higher withdrawal rate due to adverse effects compared to placebo, based on depression trial data, according to the American Gastroenterological Association 1, 2

Older guidelines from 2002 mentioned tricyclic antidepressants only as a consideration for resistant functional dyspepsia, but current evidence supports their use as a legitimate second-line option, though still with conditional recommendations due to moderate adverse effect burden, as reported by the European Society of Gastroenterology 3, 4
Counsel patients that symptom improvement may take 4-8 weeks and is unrelated to mood effects, and consider switching to a secondary amine tricyclic antidepressant if one is poorly tolerated, according to the American Gastroenterological Association 1, 2

The European Society of Gastrointestinal Endoscopy recommends H. pylori testing for all patients with functional dyspepsia, regardless of symptom duration, using stool test or breath test 5
The primary benefit of H. pylori eradication lies in the elimination of ulcer risk and mortality, with moderate evidence quality 6

The American Gastroenterological Association recommends proton pump inhibitors (PPIs) as first-line therapy for epigastric pain (ulcer-like dyspepsia), starting with standard dose (e.g., omeprazole 20 mg once daily), with moderate evidence quality 7, 6, 5
The European Society of Gastrointestinal Endoscopy suggests prokinetics as the preferred option for patients with bloating, early satiation, and dysmotility-like dyspepsia, with varying evidence quality depending on the prokinetic agent 7, 6, 8
H2-receptor antagonists are an alternative option when PPIs are not tolerated or available, although the evidence is weaker 5

The American Gastroenterological Association recommends considering a treatment withdrawal trial after initial symptom control, with re-treatment with the successful medication justified in case of symptom recurrence 7, 6
A switch from PPI to prokinetic or vice versa should be considered in case of non-response to the first-line therapy, as symptom misclassification is possible 7, 6

The European Society of Gastrointestinal Endoscopy recommends tricyclic antidepressants (TCAs) as second-line therapy for refractory symptoms, starting with low dose (e.g., amitriptyline 10 mg once daily) and titrating up to maximal 30-50 mg daily, with moderate evidence quality 5

The American Gastroenterological Association advises against using acid suppression without H. pylori eradication in H. pylori-positive patients, as this may represent inadequate treatment of a possible ulcer disease 9
The European Society of Gastrointestinal Endoscopy notes that symptom improvement after H. pylori eradication may not occur, but therapy is still justified due to the elimination of ulcer risk 6

The European Society of Gastrointestinal Endoscopy recommends regular aerobic exercise for all patients, despite very low evidence quality, and notes that special diets, including FODMAP-restricted diet, have insufficient evidence 5